Evidence map›Paper›PMID 33855792›Full record

ArticleAngewandte Chemie (International ed. in English)2021

A Two-Pronged Pulmonary Gene Delivery Strategy: A Surface-Modified Fullerene Nanoparticle and a Hypotonic Vehicle.

Daiqin Chen, Shuai Liu, Dinghao Chen, Jinhao Liu, Jerry Wu, Han Wang, Yun Su, Gijung Kwak, Xinyuan Zuo, Divya Rao and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Pulmonary Delivery of Nonviral Nucleic Acid-Based Vaccines With Spotlight on Gold Nanoparticles.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Daiqin ChenThe Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Johns Hopkins, Baltimore, MD, USA.
Shuai LiuKey Laboratory of Molecular Nanostructure and Nanotechnology, Institute of Chemistry, Chinese Academy of Sciences, Zhongguancun North First Street 2, Beijing, PR China.
Dinghao ChenThe Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Johns Hopkins, Baltimore, MD, USA.
Jinhao LiuThe Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Johns Hopkins, Baltimore, MD, USA.
Jerry WuThe Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Johns Hopkins, Baltimore, MD, USA.
Han WangDepartment of Chemical and Biomolecular Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, MD, USA.
Yun SuThe Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Johns Hopkins, Baltimore, MD, USA.
Gijung KwakThe Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Johns Hopkins, Baltimore, MD, USA.
Xinyuan ZuoThe Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Johns Hopkins, Baltimore, MD, USA.
Divya RaoThe Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Johns Hopkins, Baltimore, MD, USA.
Honggang CuiDepartment of Chemical and Biomolecular Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, MD, USA.
Chunying ShuKey Laboratory of Molecular Nanostructure and Nanotechnology, Institute of Chemistry, Chinese Academy of Sciences, Zhongguancun North First Street 2, Beijing, PR China.
Jung Soo SukThe Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Johns Hopkins, Baltimore, MD, USA.ORCID 0000-0002-2437-0001
Johns Hopkins University · USChinese Academy of Sciences · CN

Funding

Wilmer Core Grant for Vision ResearchP30EY001765 · NEI · JOHNS HOPKINS UNIVERSITY · PI Ji Yi · 1985 to 2026
$22.1M
New Inhalation Therapy for COPDR01HL136617 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI NEPTUNE, ENID R, SUK, JUNG SOO · 2017 to 2020
$1.6M
NEI NIH HHS P30 EY001765NHLBI NIH HHS R01 HL136617
6 · The paper itself

Abstract

Inhaled gene therapy poses a unique potential of curing chronic lung diseases, which are currently managed primarily by symptomatic treatments. However, it has been challenging to achieve therapeutically relevant gene transfer efficacy in the lung due to the presence of numerous biological delivery barriers. Here, we introduce a simple approach that overcomes both extracellular and cellular barriers to enhance gene transfer efficacy in the lung in vivo. We endowed tetra(piperazino)fullerene epoxide (TPFE)-based nanoparticles with non-adhesive surface polyethylene glycol (PEG) coatings, thereby enabling the nanoparticles to cross the airway mucus gel layer and avoid phagocytic uptake by alveolar macrophages. In parallel, we utilized a hypotonic vehicle to facilitate endocytic uptake of the PEGylated nanoparticles by lung parenchymal cells via the osmotically driven regulatory volume decrease (RVD) mechanism. We demonstrate that this two-pronged delivery strategy provides safe, wide-spread and high-level transgene expression in the lungs of both healthy mice and mice with chronic lung diseases characterized by reinforced delivery barriers.

Indexed as

Gene Transfer TechniquesChronic DiseaseEpoxy CompoundsFullerenesHumansLung DiseasesNanoparticlesEpoxy CompoundsFullerenesfullerenegene deliveryhypotonic vehiclesinhalationRVD effect

Identifiers

PMID33855792
PMCPMC8238871
OpenAlexW3154716789

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.